Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma
Condition(s):Malignant GliomaLast Updated:April 21, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Malignant GliomaLast Updated:April 21, 2017Completed
Condition(s):Malignant GliomaLast Updated:February 20, 2013Completed
Condition(s):Malignant Glioma; Brain Tumor, RecurrentLast Updated:March 27, 2024Completed
Condition(s):Malignant GliomaLast Updated:January 26, 2007Completed
Condition(s):Malignant GliomasLast Updated:August 22, 2012Unknown status
Condition(s):GliomasLast Updated:May 9, 2017Completed
Condition(s):Glioblastoma; Recurrent Adult Brain Neoplasm; Malignant Glioma; WHO Grade III GliomaLast Updated:April 6, 2023Active, not recruiting
Condition(s):High Grade Recurrent Glioma and Newly Diagnosed GlioblastomaLast Updated:November 7, 2023Completed
Condition(s):Radiation Toxicity; MRI Simulated Positioning; High Grade Glioma; Progression-free Survival; Overall SurvivalLast Updated:March 15, 2024Recruiting
Condition(s):Malignant Glioma; Recurrent GliomaLast Updated:June 29, 2021Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.